Smartleaf Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Smartleaf Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14.3K	Buy	321 +5	+2%	+$264	﹤0.01%	2147
2025 Q4	$16.8K	Buy	316 +85	+37%	+$5.09K	﹤0.01%	2128
2025 Q3	$14.7K	Buy	231 +51	+28%	+$2.93K	﹤0.01%	1946
2025 Q2	$8.55K	Hold	180	–	–	﹤0.01%	1878
2025 Q1	$6.66K	Hold	180	–	–	﹤0.01%	2084
2024 Q4	$6.96K	Hold	180	–	–	﹤0.01%	2138
2024 Q3	$8.52K	Buy	+180	New	+$9.13K	﹤0.01%	1859

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Smartleaf Asset Management's CRSP Position: Q1 2026 in Review

Smartleaf Asset Management increased its CRISPR Therapeutics (CRSP) stake by 1.6% in Q1 2026, buying an estimated $264 and bringing the position to 321 shares worth $14.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2147.

Smartleaf Asset Management first reported a position in CRSP in Q3 2024 and has held it in 7 quarters since. The position peaked at $16.8K in Q4 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

Smartleaf Asset Management held 321 shares of CRISPR Therapeutics worth $14.3K as of Q1 2026.
Smartleaf Asset Management bought 5 CRISPR Therapeutics shares in Q1 2026, an estimated $264.
CRISPR Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #2147 holding.
Smartleaf Asset Management first reported a position in CRISPR Therapeutics in Q3 2024 and has held it in 7 quarters since.
Smartleaf Asset Management's CRISPR Therapeutics position peaked at $16.8K in Q4 2025.
488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.